| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,448 |
2,336 |
$1.01M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
1,004 |
339 |
$370K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
836 |
298 |
$307K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
703 |
669 |
$289K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
761 |
267 |
$237K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
495 |
491 |
$206K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
500 |
474 |
$150K |
| 99218 |
|
319 |
139 |
$126K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
142 |
141 |
$59K |
| 71046 |
Radiologic examination, chest; 2 views |
479 |
467 |
$39K |
| 97535 |
Self-care/home management training, each 15 minutes |
595 |
213 |
$17K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
440 |
440 |
$14K |
| 92567 |
|
43 |
42 |
$13K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
399 |
392 |
$11K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
399 |
392 |
$11K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
356 |
307 |
$11K |
| 87070 |
|
1,109 |
1,077 |
$10K |
| 80053 |
Comprehensive metabolic panel |
762 |
703 |
$10K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,004 |
924 |
$8K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
64 |
61 |
$7K |
| 87400 |
|
267 |
266 |
$6K |
| 74018 |
|
56 |
55 |
$6K |
| 84443 |
Thyroid stimulating hormone (TSH) |
288 |
288 |
$5K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
62 |
62 |
$5K |
| 73610 |
|
40 |
39 |
$5K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
533 |
507 |
$5K |
| 86317 |
|
80 |
80 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
322 |
319 |
$4K |
| 80061 |
Lipid panel |
226 |
226 |
$4K |
| 83690 |
|
482 |
451 |
$4K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
57 |
55 |
$3K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
45 |
41 |
$3K |
| 87186 |
|
220 |
217 |
$2K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
210 |
210 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
44 |
39 |
$2K |
| 84439 |
|
193 |
193 |
$2K |
| 87147 |
|
213 |
212 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
241 |
225 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
216 |
207 |
$2K |
| 84703 |
|
207 |
195 |
$2K |
| 81001 |
|
462 |
447 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
122 |
121 |
$1K |
| 73630 |
|
12 |
12 |
$1K |
| 84702 |
|
70 |
65 |
$1K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
13 |
13 |
$1K |
| 80076 |
|
57 |
57 |
$559.44 |
| 87205 |
|
111 |
107 |
$530.07 |
| 71045 |
Radiologic examination, chest; single view |
34 |
31 |
$432.88 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
87 |
85 |
$416.02 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
49 |
43 |
$416.02 |
| 81003 |
|
165 |
163 |
$392.70 |
| 87088 |
|
40 |
40 |
$344.40 |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
13 |
13 |
$310.70 |
| 85027 |
|
43 |
42 |
$295.41 |
| 80050 |
General health panel |
13 |
13 |
$261.04 |
| 83525 |
|
18 |
18 |
$206.55 |
| 87077 |
|
14 |
14 |
$100.12 |
| 84460 |
|
12 |
12 |
$67.56 |
| 85007 |
|
14 |
14 |
$51.10 |
| 85652 |
|
15 |
15 |
$43.20 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
30 |
30 |
$27.25 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
128 |
122 |
$0.00 |
| 92579 |
|
25 |
25 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
130 |
116 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
157 |
142 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
12 |
12 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
13 |
13 |
$0.00 |